Homenko A G, Ciukanov V L
Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Pneumoftiziol. 1979 Oct-Dec;28(4):211-8.
In newly discovered patients with cavitary forms of pulmonary tuberculosis treatment with rifampicin, in association with other drugs, leads to recovery (negativation) in 69,6 percent of the patients in 3 months, in 92 per cent after 6 months and in 94,6 percent after 9 months of treatment. Closure of cavities is found in 23,4 percent, 64,5 percent and 76,6 percent of all patients at the corresponding time intervals. Comparisons of the various regimens of chemotherapy which include rifampicin showed that the maximal efficiency was obtained with rifampicin, ioniazid and a third drug (either etambutol or protionamide). The time intervals for the disappearence of bacilli and for the closure of cavities depend to a great extent on the degree of development of the pathological process, on the type of the lesions and the intensity of bacilli elimination at the start of the treatment. The use of rifampicin in new patients, in association with other drugs, leads to a rapid negativation, a shortening of the time necessary for the closure of cavities, especially in patients in whom the disappearence of the bacilli from the sputum occurs in the first three months.
在新发现的空洞型肺结核患者中，利福平联合其他药物治疗，3个月时69.6%的患者康复（痰菌转阴），6个月时为92%，9个月时为94.6%。在相应时间间隔，分别有23.4%、64.5%和76.6%的患者空洞闭合。对包括利福平在内的各种化疗方案进行比较表明，利福平、异烟肼和第三种药物（乙胺丁醇或丙硫异烟胺）联合使用时疗效最佳。细菌消失和空洞闭合的时间间隔在很大程度上取决于病理过程的发展程度、病变类型以及治疗开始时细菌清除的强度。在新患者中，利福平联合其他药物使用可导致快速痰菌转阴，缩短空洞闭合所需时间，尤其是那些在头三个月痰菌即转阴的患者。
